|
|
Vaccine Detail
|
Dendritic Cell Survivin Vaccine |
| Vaccine Information |
- Vaccine Name: Dendritic Cell Survivin Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ (NCT02851056)
- Immunization Route: Intramuscular injection (i.m.)
- Description: The Dendritic Cell Survivin Vaccine (DC:AdmS) is made using the participant's own blood cells. The vaccine will contain a virus called an adenovirus, similar the virus that causes the common cold. The dendritic cells contain survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry. The vaccine is given in combination with G-CSF, T cells, and the CD34 progenitor cells. (NCT02851056)
|
| Host Response |
|
|
| References |
NCT02851056: Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) [https://clinicaltrials.gov/study/NCT02851056]
|
|
